Company & Sponsor Intelligence
University of Cincinnati
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials13
Recruiting1
Completed10
Countries1
Therapeutic footprint
adhddepressionepilepsyother_psychiatryparkinsonsstroke
Indexed studies
NCT00526630Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
parkinsons · United StatesPHASE4
parkinsons · United StatesPHASE4
NCT05251454Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.
other_psychiatry · United StatesNA
other_psychiatry · United StatesNA
NCT02865629N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring
depression · United StatesNA
depression · United StatesNA
NCT05273398Effects of Diazepam on RNS Detections
epilepsy · United StatesPHASE4
epilepsy · United StatesPHASE4
NCT00071565Familial Intracranial Aneurysm Study II
stroke · United StatesCOMPLETED
stroke · United StatesCOMPLETED
NCT01713777Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design
epilepsy · United StatesPHASE4
epilepsy · United StatesPHASE4
NCT04404478Stress-reduction Wellness Program for Midlife Black Women (B-SWELL)
depression · United StatesNA
depression · United StatesNA
NCT02478788Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT00477802Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease
parkinsons · United StatesPHASE4
parkinsons · United StatesPHASE4
NCT01733394Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)
epilepsy · United StatesPHASE4
epilepsy · United StatesPHASE4
NCT02470780Treating Bacterial Overgrowth in Parkinson's Disease
parkinsons · United StatesPHASE2, PHASE3
parkinsons · United StatesPHASE2, PHASE3
NCT04553198Quantifying the Role of Sensory Systems Processing in Post-Stroke Walking Recovery
stroke · United StatesNA
stroke · United StatesNA
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →